Midline Compared With Peripheral Intravenous Catheters for Therapy of 4 Days or Longer in Pediatric Patients
JAMA Pediatrics · 01.11.2023 · 177 (11) · 1132
DOI: 10.1001/jamapediatrics.2023.3526 ↗Kurz gefasst
Pragmatische Studie in der Zeitschrift JAMA Pediatrics, erschienen am 01.11.2023. Verfasst von Tricia M Kleidon und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesia and Pain, Children's Health Queensland Hospital and Health Service, Queensland Children's Hospital, Brisbane, Queensland, A…. Hauptthemen laut MEDLINE: Catheterization, Peripheral. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Peripheral intravenous catheters (PIVCs) frequently fail during treatment causing therapy interruption, pain, recatheterization, and additional health care costs. Midline catheters (MCs) may improve functional dwell time and reduce failure compared with traditional PIVCs.
Objective
To compare device failure of MCs with PIVCs Design, Setting, and Participants This was a pragmatic, randomized clinical superiority trial with an embedded internal pilot study conducted from July 2020 to May 2022. The study took place in a quaternary pediatric hospital in Brisbane, Queensland, Australia. Inclusion criteria were patients aged 1 to 18 years requiring peripherally compatible intravenous therapy for 4 days or longer.
Interventions
Patients were randomly assigned 1:1 to receive a PIVC or MC, stratified by age (≤5 years, >5 years). One catheter was studied per patient. Main Outcomes and Measures The primary outcome was all-cause device failure, defined as premature cessation of device function. Secondary outcomes included number of insertion attempts, insertion failure, pain (on insertion), procedural time, patient/parent satisfaction (with insertion), device dwell time, device complications during dwell time, additional vascular access devices required to complete treatment, clinician satisfaction (at removal), and health care costs.
Results
Of the 128 patients randomly assigned to study groups, 127 patients (median [IQR] age, 7 [2-13] years; 71 male [56%]) had a device inserted, with 65 (51.2%) in the PIVC group and 62 (48.8%) in the MC group. All patients were included in the intention-to-treat analysis. Device failure was lower in patients in the MC group (10 [16.1%]) compared with those in the PIVC group (30 [46.2%]; odds ratio [OR], 0.22; 95% CI, 0.10-0.52; P <.001). MCs were associated with fewer insertion attempts (mean difference [MD], −0.3; 95% CI, −0.5 to 0; P = .04), increased dwell time (MD, 66.9 hours; 95% CI, 36.2-97.5 hours; P <.001), and fewer patients required additional vascular access devices to complete treatment in the MC group (4 [6.5%]) and PIVC group (19 [29.2%]; OR, 0.17; 95% CI, 0.05-0.52; P = .002). Compared with PIVCs, use of MCs was associated with greater patient (9.0 vs 7.1 of 10; P = .002) and parent (9.1 vs 8.2 of 10; P = .02) satisfaction and lower health care costs (AUS −$151.67 [US −$101.13] per person; 95% credible interval, AUS −$171.45 to −$131.90 [US −$114.20 to −$87.95]). Conclusions and Relevance Findings suggest that MC insertion for patients requiring peripherally compatible intravenous therapy for 4 days or longer should be prioritized to reduce the resource intensive, expensive, and burdensome sequelae of device failure. Trial Registration Australia New Zealand Clinical Trials Registry, ACTRN12620000724976
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Anaesthesia and Pain, Children's Health Queensland Hospital and Health Service, Queensland Children's Hospital, Brisbane, Queensland, Australia.
- School of Nursing, Midwifery and Social Work, The University of Queensland, Brisbane, Queensland, Australia.
- Alliance for Vascular Access Teaching and Research, Griffith University, Brisbane, Queensland, Australia.
- Nursing and Midwifery Research Centre, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
- Herston Infectious Diseases Institute, Metro North Hospital and Health Service, Brisbane, Queensland, Australia.
- Menzies Health Institute Queensland, Griffith University, Nathan, Queensland, Australia.
Zitieren
APA
Kleidon, T. M., Gibson, V., Cattanach, P., Schults, J., Royle, R. H., Ware, R. S., Marsh, N., Pitt, C., Dean, A., Byrnes, J., Rickard, C. M., & Ullman, A. J. (2023). Midline Compared With Peripheral Intravenous Catheters for Therapy of 4 Days or Longer in Pediatric Patients. JAMA Pediatrics, 177(11), 1132. https://doi.org/10.1001/jamapediatrics.2023.3526
Vancouver
Kleidon TM, Gibson V, Cattanach P, Schults J, Royle RH, Ware RS, et al. Midline Compared With Peripheral Intravenous Catheters for Therapy of 4 Days or Longer in Pediatric Patients. JAMA Pediatrics. 2023;177(11):1132. doi:10.1001/jamapediatrics.2023.3526
BibTeX
@article{Kleidon2023,
author = {Kleidon, Tricia M and Gibson, Victoria and Cattanach, Paula and Schults, Jessica and Royle, Ruth H and Ware, Robert S and Marsh, Nicole and Pitt, Colleen and Dean, Anna and Byrnes, Joshua and Rickard, Claire M and Ullman, Amanda J},
title = {Midline Compared With Peripheral Intravenous Catheters for Therapy of 4 Days or Longer in Pediatric Patients},
journal = {JAMA Pediatrics},
year = {2023},
volume = {177},
number = {11},
pages = {1132},
doi = {10.1001/jamapediatrics.2023.3526}
}
EUVIMED